|
**Overview**: Breast Monitor Panel**Introduction**: The Breast Monitor Panel is a diagnostic tool designed to monitor breast cancer progression using serum samples. In India, breast cancer patients require regular marker monitoring (CA 15.3, CA 27.29) for early detection of recurrence or metastasis (recurrence in 20-30 percent within 5 years). High burden in women, underdiagnosis of progression in rural areas, limited oncology follow-up. Per oncology practices aligned with ICMR guidelines, the test employs immunoassay for marker analysis over 1-2 days with high sensitivity/specificity, valuable for surveillance. This diagnostic falls under cancer monitoring and targets breast cancer patients, addressing accurate detection to guide therapy adjustments. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise monitoring and improving outcomes. Its serum-based approach ensures reliable detection.**Other Names**: Breast Mon Pnl.**FDA Status**: FDA approved, CLIA certified for oncology, compliant with 2025 standards.**Historical Milestone**: Tumor markers standard; in India, used in breast cancer follow-up.**Purpose**: The test monitors 2 parameters including CA 15.3 to guide breast cancer progression assessment, detect recurrence, inform treatment.**Test Parameters**: 1. CA 15.3, 2. CA 27.29.**Pretest Condition**: No fasting required; patients should report breast cancer history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on cancer stage, treatment, symptoms.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected progression, benefits of monitoring, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store kits according to manufacturer specifications to ensure reliability.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis, or concurrent illnesses can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Elevated markers indicate progression, necessitating specialist input. Normal may require follow-up if symptoms.**Specialist Consultation**: Oncologists should be consulted for management.**Additional Supporting Tests**: Imaging for confirmation.**Test Limitations**: Markers may not be specific; comprehensive approach required.**References**: Indian Journal of Medical Oncology 2024, Breast Cancer Studies India 2023. |
